Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Vanessa Raymont


Associate Professor, R&D Director Oxford Health NHS Foundation Trust

  • Honorary Senior Clinical Research Fellow, University of Edinburgh
  • Honorary Consultant Psychiatrist

My clinical and research interests are in traumatic brain injury, and memory disorders and dementia, as well as clinical trials in cognitive impairment, having worked for over 25 years in clinical trials in the UK and US. 

I am currently the Principal Investigator for the New Therapeutics in Alzheimer’s Disease (NTAD), Brains for Dementia Research (BDR) and 7Tesla MRI Scanning in Alzheimer’s disease and Frontotemporal Lobar Degeneration studies and Chief Investigator on the  Deep and Frequent Phenotyping (DFP) study and a NHIR-funded study assessing the use of sertraline to prevent post-head injury depression (STOP-D). I am co-lead for the Clinical Trials section of Oxford Translational Neuroscience and Dementia Research Group and NIHR Dementia Lead for the Thames Valley and South Midlands Clinical Research Network. I am an associate director of Dementia Platforms UK, and workstream lead for the Trials Delivery Framework. I serve as a Commissioner for the Commission on Human Medicines and am co-Deputy Chair of the NIHR Dementia Translational Research Collaboration.

Recent publications

More publications